CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $714 | +41.7% | 11,100 | 0.0% | 0.01% | +33.3% |
| Q3 2023 | $504 | -19.1% | 11,100 | 0.0% | 0.01% | -18.2% |
| Q2 2023 | $623 | +24.1% | 11,100 | 0.0% | 0.01% | +10.0% |
| Q1 2023 | $502 | +11.3% | 11,100 | 0.0% | 0.01% | +11.1% |
| Q4 2022 | $451 | -99.9% | 11,100 | 0.0% | 0.01% | -43.8% |
| Q3 2022 | $725,000 | +133.9% | 11,100 | +117.6% | 0.02% | +166.7% |
| Q2 2022 | $310,000 | -63.7% | 5,100 | -62.5% | 0.01% | -60.0% |
| Q1 2022 | $854,000 | -17.2% | 13,600 | 0.0% | 0.02% | -11.8% |
| Q4 2021 | $1,031,000 | – | 13,600 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |